Nano-X Imaging (Nanox) is reporting stable revenue for the second quarter of the 2024 fiscal year, which ended June 30.
The company generated $2.7 million in revenue for the quarter compared with $2.6 million for the same period in 2023. It also reported a decrease in net loss between the 2023 and 2024 second quarters, posting a loss of $13.6 million this year compared with a $17.4 million loss in 2023.
Among Nanox's highlights from the quarter include submitting a 510(k) clearance submission to the U.S. Food and Drug Administration (FDA) for the Nanox.ARC for general use, including the chest, as well as receiving FDA clearance for its HealthCCSng V2.0.
